Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $80.63

Pacira BioSciences, Inc. (NASDAQ:PCRX – Get Rating) has earned an average recommendation of “Buy” from the ten research firms that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $80.63.

PCRX has been the topic of several research reports. Northland Securities upped their price objective on Pacira BioSciences from $61.00 to $67.00 in a report on Tuesday, March 1st. StockNews.com initiated coverage on Pacira BioSciences in a report on Thursday, March 31st. They set a “hold” rating on the stock. HC Wainwright upped their price objective on Pacira BioSciences from $86.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, February 25th. Wedbush reiterated a “buy” rating and set a $94.00 target price (down previously from $97.00) on shares of Pacira BioSciences in a research report on Saturday, February 26th. Finally, TheStreet cut shares of Pacira BioSciences from a “b-” rating to a “c” rating in a research report on Thursday, February 24th.

In other news, SVP Lauren Bullaro Riker sold 9,300 shares of Pacira BioSciences stock in a transaction on Thursday, March 10th. The shares were sold at an average price of $71.22, for a total transaction of $662,346.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Kristen Marie Williams sold 2,050 shares of Pacira BioSciences stock in a transaction on Friday, February 25th. The stock was sold at an average price of $67.02, for a total transaction of $137,391.00. The disclosure for this sale can be found here. Insiders sold 69,607 shares of company stock worth $5,092,865 in the last 90 days. Company insiders own 5.20% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Pacira BioSciences by 0.5% during the first quarter. Vanguard Group Inc. now owns 4,688,119 shares of the company’s stock worth $357,797,000 after buying an additional 22,164 shares during the last quarter. Baillie Gifford & Co. raised its stake in Pacira BioSciences by 12.8% during the fourth quarter. Baillie Gifford & Co. now owns 2,355,240 shares of the company’s stock worth $141,714,000 after buying an additional 267,433 shares during the last quarter. Spyglass Capital Management LLC raised its stake in Pacira BioSciences by 4.4% during the third quarter. Spyglass Capital Management LLC now owns 2,211,210 shares of the company’s stock worth $123,828,000 after buying an additional 93,537 shares during the last quarter. Renaissance Technologies LLC increased its stake in Pacira BioSciences by 0.6% in the first quarter. Renaissance Technologies LLC now owns 1,860,997 shares of the company’s stock valued at $142,031,000 after purchasing an additional 11,800 shares in the last quarter. Finally, Paulson & CO. Inc. increased its stake in Pacira BioSciences by 35.4% in the fourth quarter. Paulson & CO. Inc. now owns 1,705,599 shares of the company’s stock valued at $102,626,000 after purchasing an additional 446,081 shares in the last quarter.

NASDAQ PCRX traded up $0.48 during trading on Friday, reaching $61.13. 1,738 shares of the company traded hands, compared to its average volume of 536,070. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.85 and a current ratio of 2.19. The stock’s 50 day moving average price is $71.52 and its two-hundred day moving average price is $64.97. The company has a market cap of $2.78 billion, a price-to-earnings ratio of 72.20 and a beta of 0.88. Pacira BioSciences has a 1-year low of $45.05 and a 1-year high of $82.16.

Pacira BioSciences (NASDAQ:PCRX – Get Rating) last announced its earnings results on Wednesday, May 4th. The company reported $0.64 EPS for the quarter, missing the consensus estimate of $0.83 by ($0.19). The business had revenue of $157.99 million during the quarter, compared to analyst estimates of $155.08 million. Pacira BioSciences had a return on equity of 15.17% and a net margin of 6.62%. The firm’s revenue was up 32.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.37 earnings per share. Equities research analysts expect that Pacira BioSciences will post 2.95 EPS for the current fiscal year.

Pacira BioSciences Company Profile (Get Rating)

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.

See Also